Genomic Health (GHDX) Releases Earnings Results, Reports EPS of $-0.18 EPS

Genomic Health (GHDX) reported quarterly earnings results on Tuesday, Aug-2-2016. The company reported $-0.18 EPS for the quarter. Analysts had a consensus estimate of $-0.18. The company posted revenue of $81.97 million in the period, compared to analysts expectations of $81.18 million. The company’s revenue was up 16.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.29 EPS.

Genomic Health opened for trading at $28.58 and hit $29.13 on the upside on Friday, eventually ending the session at $29.03, with a gain of 1.04% or 0.3 points. The heightened volatility saw the trading volume jump to 1,27,149 shares. Company has a market cap of $958 M.

In a different news, on Jul 8, 2016, G Bradley Cole (COO) sold 5,000 shares at $26.65 per share price. According to the SEC, on Jun 23, 2016, Steven Shak (Chief Scientific Officer) sold 5,000 shares at $26.21 per share price. On Jun 8, 2016, James J Vaughn (Chief Commercial Officer) sold 1,997 shares at $28.00 per share price, according to the Form-4 filing with the securities and exchange commission.

Genomic Health Inc. is a healthcare company that provides actionable genomic information to personalize cancer treatment decisions. The Company offers its Oncotype DX tests as a clinical laboratory service where it analyzes the expression levels of genes in tumor tissue samples and provides physicians with a quantitative gene expression profile expressed as a single quantitative score which it calls a Recurrence Score for invasive breast cancer and colon cancer a DCIS Score for ductal carcinoma in situ (DCIS) and a Genomic Prostate Score (GPS) for prostate cancer. The Company’s Oncotype DX platform utilizes quantitative genomic analysis known as reverse transcription polymerase chain reaction (RT-PCR) in standard tumor pathology specimens to provide tumor-specific information or the oncotype of a tumor. Its offerings also include Oncotype DX Breast Cancer Test Oncotype DX Colon Cancer Test and Oncotype DX Prostate Cancer Test.

Genomic Health

Leave a Reply

Genomic Health - Is it time to Sell?

Top Brokerage Firms are advising their investors on Genomic Health. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.